C Agalar1, S Sokmen2, C Arslan3, C Altay4, I Basara4, A E Canda2, F Obuz4. 1. Department of General Surgery, Faculty of Medicine, Dokuz Eylul University, Balcova, Izmir, Turkey. cihan.agalar@deu.edu.tr. 2. Department of General Surgery, Faculty of Medicine, Dokuz Eylul University, Balcova, Izmir, Turkey. 3. Department of General Surgery, Faculty of Medicine, Medipol University, Istanbul, Turkey. 4. Department of Radiology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Abstract
BACKGROUND: The aim of this study was to evaluate the prognostic value of preoperative sarcopenia with regard to postoperative morbidity and long-term survival in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: A longitudinal cohort study was conducted on patients with peritoneal metastases of colorectal origin treated with CRS-HIPEC between 2008 and 2018. Data on patient demographics, body mass index, operative characteristics, perioperative morbidity and survivorship status and oncological follow-up were obtained from the hospital registry. Sarcopenia was assessed using preoperative computed tomography (CT) findings. RESULTS: Sixty-five patients [mean (SD) age: 54.4 (13.4) years, 64.6% females] were included in the study. Sarcopenia was evident in 30.8% of patients, while mortality rate was 66.2% with median survival time of 33.6 months. Presence of sarcopenia was associated with older age (59.6 (9.2) vs. 52.1 (14.4) years, p = 0.038), higher likelihood of morbidity (70.0% vs. 35.6%, p = 0.015) and mortality (90.0% vs. 55.6%, p = 0.010) and shorter survival time (17.7 vs. 37.9 months, p = 0.005). Cox regression analysis revealed that the presence of sarcopenia (HR 2.245, 95% CI 0.996-5.067, p = 0.050) was a significant predictor of increased likelihood of mortality. CONCLUSIONS: Preoperative sarcopenia is an independent prognostic factor of postoperative morbidity and shorter survival in CRC peritoneal metastasis patients treated with CRS-HIPEC. Our findings support the importance of preoperative screening for sarcopenia as part of preoperative risk assessment for better selection of CRS-HIPEC candidates or treatment modifications in CRC patients with peritoneal metastasis.
BACKGROUND: The aim of this study was to evaluate the prognostic value of preoperative sarcopenia with regard to postoperative morbidity and long-term survival in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: A longitudinal cohort study was conducted on patients with peritoneal metastases of colorectal origin treated with CRS-HIPEC between 2008 and 2018. Data on patient demographics, body mass index, operative characteristics, perioperative morbidity and survivorship status and oncological follow-up were obtained from the hospital registry. Sarcopenia was assessed using preoperative computed tomography (CT) findings. RESULTS: Sixty-five patients [mean (SD) age: 54.4 (13.4) years, 64.6% females] were included in the study. Sarcopenia was evident in 30.8% of patients, while mortality rate was 66.2% with median survival time of 33.6 months. Presence of sarcopenia was associated with older age (59.6 (9.2) vs. 52.1 (14.4) years, p = 0.038), higher likelihood of morbidity (70.0% vs. 35.6%, p = 0.015) and mortality (90.0% vs. 55.6%, p = 0.010) and shorter survival time (17.7 vs. 37.9 months, p = 0.005). Cox regression analysis revealed that the presence of sarcopenia (HR 2.245, 95% CI 0.996-5.067, p = 0.050) was a significant predictor of increased likelihood of mortality. CONCLUSIONS: Preoperative sarcopenia is an independent prognostic factor of postoperative morbidity and shorter survival in CRC peritoneal metastasis patients treated with CRS-HIPEC. Our findings support the importance of preoperative screening for sarcopenia as part of preoperative risk assessment for better selection of CRS-HIPEC candidates or treatment modifications in CRCpatients with peritoneal metastasis.
Authors: Kostan W Reisinger; Jeroen L A van Vugt; Juul J W Tegels; Claire Snijders; Karel W E Hulsewé; Anton G M Hoofwijk; Jan H Stoot; Maarten F Von Meyenfeldt; Geerard L Beets; Joep P M Derikx; Martijn Poeze Journal: Ann Surg Date: 2015-02 Impact factor: 12.969
Authors: Pierre A Clavien; Jeffrey Barkun; Michelle L de Oliveira; Jean Nicolas Vauthey; Daniel Dindo; Richard D Schulick; Eduardo de Santibañes; Juan Pekolj; Ksenija Slankamenac; Claudio Bassi; Rolf Graf; René Vonlanthen; Robert Padbury; John L Cameron; Masatoshi Makuuchi Journal: Ann Surg Date: 2009-08 Impact factor: 12.969
Authors: Jeroen L A van Vugt; Hidde J Braam; Thijs R van Oudheusden; Asra Vestering; Thomas L Bollen; Marinus J Wiezer; Ignace H J T de Hingh; Bert van Ramshorst; Djamila Boerma Journal: Ann Surg Oncol Date: 2015-02-12 Impact factor: 5.344
Authors: Carla M M Prado; Jessica R Lieffers; Linda J McCargar; Tony Reiman; Michael B Sawyer; Lisa Martin; Vickie E Baracos Journal: Lancet Oncol Date: 2008-06-06 Impact factor: 41.316
Authors: James R Broughman; Grant R Williams; Allison M Deal; Hyeon Yu; Kirsten A Nyrop; Shani M Alston; Brittaney-Belle Gordon; Hanna K Sanoff; Hyman B Muss Journal: J Geriatr Oncol Date: 2015-09-11 Impact factor: 3.599
Authors: Carla M M Prado; Vickie E Baracos; Linda J McCargar; Marina Mourtzakis; Karen E Mulder; Tony Reiman; Charles A Butts; Andrew G Scarfe; Michael B Sawyer Journal: Clin Cancer Res Date: 2007-06-01 Impact factor: 12.531
Authors: Stefano Rotolo; Andrea Di Giorgio; Marco Cintoni; Emanuele Rinninella; Marta Palombaro; Gabriele Pulcini; Carlo Alberto Schena; Vito Chiantera; Giuseppe Vizzielli; Antonio Gasbarrini; Fabio Pacelli; Maria Cristina Mele Journal: Pleura Peritoneum Date: 2022-03-01
Authors: Devon C Freudenberger; Vignesh Vudatha; Andrea N Riner; Kelly M Herremans; Leopoldo J Fernandez; Jose G Trevino Journal: Cancers (Basel) Date: 2022-06-09 Impact factor: 6.575